Christopher Missling - Apr 28, 2025 Form 4 Insider Report for ANAVEX LIFE SCIENCES CORP. (AVXL)

Role
President and CEO, Director
Signature
/s/Christopher Missling
Stock symbol
AVXL
Transactions as of
Apr 28, 2025
Transactions value $
$0
Form type
4
Date filed
4/30/2025, 08:00 PM
Previous filing
Mar 26, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVXL Stock Option (Right to Buy) Award $0 +125K $0.00 125K Apr 28, 2025 Common Stock 125K $8.57 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 31, 2023, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was completion of enrollment of ANAVEX3-71 Phase 2 clinical trial in Schizophrenia. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.